D
HLS Therapeutics Inc. HLS.TO
TSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

06/30/2025 03/31/2025 12/31/2024 09/30/2024 06/30/2024
Revenue -2.40% 1.20% -2.02% -12.17% -11.56%
Total Other Revenue -- -- -- -- --
Total Revenue -2.40% 1.20% -2.02% -12.17% -11.56%
Cost of Revenue 3.98% 26.16% 7.78% 3.64% 15.84%
Gross Profit -4.59% -6.84% -5.24% -16.66% -18.23%
SG&A Expenses -19.67% -19.52% 3.02% -7.47% -11.10%
Depreciation & Amortization -6.37% -9.44% -22.89% -32.89% -30.00%
Other Operating Expenses -- -- -- -- --
Total Operating Expenses -9.64% -7.07% -6.64% -16.33% -14.79%
Operating Income 61.58% 36.82% 72.88% 38.14% 32.45%
Income Before Tax -55.60% 27.32% 44.84% 33.06% 82.77%
Income Tax Expenses -94.06% 20.69% 13.33% 86.08% 3,383.76%
Earnings from Continuing Operations 51.76% 27.35% 44.03% 29.81% 39.79%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income 51.76% 27.35% 44.03% 29.81% 39.79%
EBIT 61.58% 36.82% 72.88% 38.14% 32.45%
EBITDA 22.81% 29.29% -13.38% -29.76% -28.63%
EPS Basic 51.65% 27.04% -14.76% 28.79% 38.62%
Normalized Basic EPS 49.75% 26.92% -22.42% 6.43% 7.53%
EPS Diluted 50.00% 26.78% -19.54% 28.79% 38.31%
Normalized Diluted EPS 49.75% 26.92% -22.42% 6.43% 7.53%
Average Basic Shares Outstanding -0.24% -0.46% -4.85% -1.42% -1.95%
Average Diluted Shares Outstanding -0.24% -0.46% -4.85% -1.42% -1.95%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --